Alexey Fayzullin | Medicine and Dentistry | Pioneer Researcher Award

Published on by Shen Awards

Dr. Alexey Fayzullin | Medicine and Dentistry | Pioneer Researcher Award

Sechenov University, Russia

Dr. Alexey Fayzullin, PhD, MD, is a distinguished medical scientist specializing in regenerative medicine, computational pathology, and digital biomedical technologies, with a strong academic and research foundation at Sechenov University, Russia. He completed his general medical studies at the International School “Medicine of the Future” (2011–2017) and earned his PhD in anatomical pathology in 2022, with a thesis on antifibrotic scaffolds in regenerative medicine. His professional journey began as a laboratory assistant (2018–2019) and junior researcher (2019–2023) in the Laboratory of Experimental Morphology at the Institute for Regenerative Medicine, before advancing to Head of the Laboratory of Digital Microscopic Analysis in 2023. His research interests span tissue engineering, artificial intelligence in histological image analysis, cell therapy, biophotonics, implantology, and computational biomedicine. With 47 peer-reviewed publications, 626 citations, and an h-index of 12, Dr. Fayzullin has contributed significantly to scientific knowledge, with his works appearing in internationally recognized journals and conferences. His research experience includes prestigious internships at Macquarie University and the University of New South Wales, where he collaborated on advanced bioengineering projects. He has won multiple competitive grants and awards, including several Russian Presidential Scholarships for international research, grants from the Russian Science Foundation (RSF) and Russian Foundation for Basic Research (RFBR), and the establishment of his own laboratory under the Priority 2030 program. His skills include advanced digital microscopy, AI-based image processing, regenerative scaffold design, project leadership, and academic mentoring. As an educator, he has co-authored Russia’s first regenerative medicine handbook, designed specialized academic courses, and supervises PhD and undergraduate students. Dr. Fayzullin’s honors, leadership roles, and international collaborations highlight his impact on both science and education. In conclusion, his remarkable achievements, innovative research, and commitment to biomedical advancement demonstrate why he is an emerging leader with the potential to shape the future of global regenerative medicine and digital healthcare.

Profile: Scopus | ORCID | Google Scholar

Featured Publications

Valieva, Y., Ivanova, E., Fayzullin, A., Kurkov, A., & Igrunkova, A. (2022). Senescence-associated β-galactosidase detection in pathology. Diagnostics, 12(10), 2309. Cited 146 times

Shekhter, A. B., Fayzullin, A. L., Vukolova, M. N., Rudenko, T. G., Osipycheva, V. D., & Litvitsky, P. F. (2019). Medical applications of collagen and collagen-based materials. Current Medicinal Chemistry, 26(3), 506–516. Cited 129 times

Deng, W., McKelvey, K. J., Guller, A., Fayzullin, A., Campbell, J. M., Clement, S., & Saunders, C. M. (2020). Application of mitochondrially targeted nanoconstructs to neoadjuvant X-ray-induced photodynamic therapy for rectal cancer. ACS Central Science, 6(5), 715–726. Cited 88 times

Fayzullin, A., Bakulina, A., Mikaelyan, K., Shekhter, A., & Guller, A. (2021). Implantable drug delivery systems and foreign body reaction: Traversing the current clinical landscape. Bioengineering, 8(12), 205. Cited 73 times

Fayzullin, A., Churbanov, S., Ignatieva, N., Zakharkina, O., Tokarev, M., & Shekhter, A. (2021). Local delivery of pirfenidone by PLA implants modifies foreign body reaction and prevents fibrosis. Biomedicines, 9(8), 853. Cited 35

Shekhter, A. B., Pekshev, A. V., Vagapov, A. B., Telpukhov, V. I., Panyushkin, P. V., Fayzullin, A. L., & Vanin, A. F. (2019). Physicochemical parameters of NO-containing gas flow affect wound healing therapy: An experimental study. European Journal of Pharmaceutical Sciences, 128, 193–201. Cited 34

Giovanni Musso | Medicine and Dentistry | Best Researcher Award

Published on by Shen Awards

Giovanni Musso | Medicine and Dentistry | Best Researcher Award

AOU San Luigi Gonzaga Orbassano (Torino), Italy

Dr. Giovanni Musso is a renowned clinician and researcher in Internal Medicine with a distinguished academic and professional career. He graduated in Medicine in 1996 with top honors (110/110) and completed his specialization in Internal Medicine in 2002 with distinction. Currently serving at the Department of Internal Medicine, Humanitas Gradenigo Hospital, Turin, he has devoted his career to the study of lipid and glucose metabolism, with particular emphasis on non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), and related metabolic complications. He leads international collaborative research involving 34 centers worldwide, producing high-impact findings on NAFLD epidemiology, pathogenesis, and staging, with publications in PLOS Medicine, Hepatology, Gastroenterology, BMJ, and other leading journals. His research interests include lipidomics, postprandial metabolism, gut microbiota, metabolic inflammation, and therapeutic innovations such as curcumin-based interventions and endoscopic approaches for metabolic disorders. His research skills span clinical trials, meta-analyses, translational studies, and consensus guideline development. Recognized globally, Dr. Musso has authored 101 documents, accrued 12,017 citations, and holds an impressive h-index of 49 (Sept 2025). His honors include co-authoring international consensus statements and leading global research collaborations. With his proven excellence in research, teaching, and clinical innovation, Dr. Musso continues to advance the field of hepatology and metabolic medicine while shaping future directions in precision healthcare.

Profile: Scopus | ORCID

Featured Publications

  • Musso, G., Mariano, F., Mella, A., Pinach, S., & Gambino, R. (2025, August 7). Meal-Induced NF-κB Activation in Mononuclear Cells Triggers Lumican Secretion and Promotes Chronic Kidney Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease. MedComm, 6(8), e70122.

  • Carpenito, N., Leporati, M., Sciarrillo, A., Pensa, A., Gambino, R., Musso, G., Mella, A., Biancone, L., Risso, D., Mariano, F., & Cosseddu, D. (2025, May 16). LC-MS/MS Determination of Quorum Sensing Molecules in Plasma from Burn Patients with Septic Shock Sustained by Acinetobacter baumannii. Antibiotics (Basel), 14(5), 517.

  • Musso, G., Mella, A., Mariano, F., Cassader, M., De Michieli, F., Riva, A., Petrangolini, G., Togni, S., Pinach, S., & Gambino, R. (2024). Impaired Postprandial GLP-2 Response Enhances Endotoxemia, Systemic Inflammation, and Kidney Injury in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Effect of Phospholipid Curcumin Meriva. Gut Microbes, 16(1), article 2424907.

  • Musso, G., Pinach, S., Mariano, F., Saba, F., De Michieli, F., Framarin, L., Berrutti, M., Paschetta, E., Parente, R., Lizet Castillo, Y., Leone, N., Castellino, F., Cassader, M., & Gambino, R. (2025, February 1). Effect of Phospholipid Curcumin Meriva® on Liver Histology and Kidney Disease in Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial. Hepatology, 81(2), 560–575.

  • Musso, G., Pinach, S., Saba, F., De Michieli, F., Cassader, M., & Gambino, R. (2024, July). Endoscopic Duodenal Mucosa Ablation Techniques for Diabetes and Nonalcoholic Fatty Liver Disease

 

Sotiri Stathakis | Medicine and Dentistry | Best Researcher Award

Published on by Shen Awards

Dr. Sotiri Stathakis | Medicine and Dentistry | Best Researcher Award

Mary Bird Perkins Cancer Center | United States

Dr. Sotirios Stathakis is an accomplished medical physicist with extensive experience in radiation oncology, advanced treatment planning, and patient safety in cancer care. Currently serving as the Chief of Physics at Mary Bird Perkins Cancer Center and Adjunct Professor at Louisiana State University, he has established himself as a leader in both clinical and academic domains. His work bridges fundamental research and real-world clinical application, focusing on improving the accuracy, efficiency, and safety of radiotherapy treatments. With a career spanning over two decades, Dr. Stathakis has played a pivotal role in advancing technologies such as intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), Monte Carlo simulations, and adaptive radiotherapy. He has supervised graduate students, medical residents, and postdoctoral fellows, contributing to the development of the next generation of medical physicists. Dr. Stathakis is internationally recognized for his innovative contributions to medical physics, publishing widely in peer-reviewed journals and presenting at global conferences. His leadership in quality assurance (QA) protocols, radiotherapy safety standards, and patient-centered innovations has earned him professional recognition as a Fellow of the American Association of Physicists in Medicine (AAPM). He continues to expand his research by integrating artificial intelligence, patient education, and wearable technology into cancer care.

Professional Profile

Scopus | ORCID

Education

Dr. Sotirios Stathakis has a strong academic background rooted in physics and medical physics, which forms the foundation of his distinguished career in cancer treatment and research. He began his academic journey with a Bachelor of Science in Physics from the University of Waterloo, Canada, where he developed a strong foundation in core physical sciences and problem-solving skills. Driven by an interest in applying physics to medicine, he pursued a Master of Science in Medical Physics at the University of Aberdeen, United Kingdom. Here, he received specialized training in radiological sciences, medical imaging, and radiotherapy applications, which fueled his passion for research in patient care. His academic progression culminated in a Ph.D. in Medical Physics from the University of Patras, Greece, where his doctoral work focused on advanced radiation dosimetry and optimization of treatment planning systems. His doctoral training allowed him to explore Monte Carlo simulations and radiation safety protocols, which later became key aspects of his professional contributions. This comprehensive education, spanning North America and Europe, equipped him with a unique global perspective and multidisciplinary expertise. It also prepared him to integrate clinical practice with research, ultimately shaping his career as a recognized leader in medical physics and radiation oncology.

Professional Experience

Dr. Sotirios Stathakis has accumulated diverse professional experience that reflects his dual commitment to academic research and clinical application. He began his career in Europe, contributing to medical physics research before moving to the United States, where he established himself in leading academic and clinical institutions. At the University of Texas Health Science Center San Antonio (UTHSA), he served as a Professor and Medical Physicist, taking on responsibilities that included treatment planning, clinical implementation of new radiotherapy techniques, and the supervision of graduate students and medical residents. His academic contributions included teaching advanced courses in radiation oncology physics and mentoring Ph.D. dissertations. He later transitioned to his current role as Chief of Physics at Mary Bird Perkins Cancer Center, where he oversees medical physics operations across multiple oncology centers. In this role, he leads a team of physicists and ensures the safe and effective delivery of radiation treatments to cancer patients. His position as Adjunct Professor at Louisiana State University complements his clinical work, as he continues to teach and mentor the next generation of medical physicists. Throughout his career, Dr. Stathakis has balanced leadership, clinical service, and research, contributing to advancements in both patient care and academic knowledge.

Research Interests

Dr. Sotirios Stathakis’s research interests lie at the intersection of clinical innovation, radiation therapy optimization, and patient-centered approaches. A central focus of his research is the improvement of treatment planning systems, particularly through advanced modeling such as Monte Carlo simulations, which enhance accuracy in dose calculations. He has contributed to the development and refinement of quality assurance (QA) protocols, ensuring precision in intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT). Another important area of his research includes studying the secondary cancer risks associated with radiotherapy, providing valuable insights into long-term patient safety. Dr. Stathakis is also exploring the role of artificial intelligence (AI) in radiotherapy, particularly for dose prediction and workflow optimization, which has the potential to revolutionize clinical practices. In recent years, he has expanded his focus to include patient-centered technologies, such as wearable monitoring devices and virtual reality tools that improve patient education, engagement, and treatment compliance. His interdisciplinary approach combines physics, engineering, computer science, and clinical oncology, creating innovative solutions to complex healthcare challenges. By bridging these fields, Dr. Stathakis continues to advance the standards of radiotherapy, contributing to safer, more effective, and personalized cancer treatments.

Research Skills

Dr. Sotirios Stathakis possesses a broad range of research skills that span computational modeling, experimental validation, clinical trial design, and academic mentoring. His expertise in Monte Carlo simulations allows him to perform highly accurate radiation dose calculations, a critical aspect of treatment planning and safety assessment in radiation oncology. He is also highly skilled in advanced quality assurance techniques, particularly for IMRT and VMAT, ensuring reliable and precise delivery of radiation therapy. Dr. Stathakis is proficient in using and commissioning treatment planning systems and linear accelerators, applying both theoretical and practical approaches to improve clinical workflows. His research methodology incorporates statistical analysis, machine learning, and artificial intelligence, enabling him to address complex problems in treatment optimization and patient safety. Beyond technical skills, he excels in collaborative project management, coordinating interdisciplinary teams across physics, medicine, and engineering. His experience extends to academic publishing, peer review, and conference presentations, reflecting his ability to effectively disseminate scientific findings. As a mentor and educator, he has guided Ph.D. students and medical residents in developing independent research projects, further demonstrating his leadership in research environments. Collectively, these skills highlight his ability to translate advanced scientific concepts into practical innovations that benefit cancer patients worldwide.

Awards and Honors

Throughout his career, Dr. Sotirios Stathakis has received numerous awards and honors in recognition of his academic excellence, clinical leadership, and professional service. One of the most prestigious distinctions in his career is being named a Fellow of the American Association of Physicists in Medicine (AAPM), a recognition reserved for members who have made significant contributions to the advancement of medical physics. He is also board-certified in Therapeutic Radiologic Physics by the American Board of Radiology (ABR), underscoring his professional expertise and credibility in clinical practice. His academic work has been acknowledged through invitations to present at leading international conferences, including those organized by IEEE, AAPM, and ESTRO, where he has shared groundbreaking findings on radiotherapy optimization and quality assurance. In addition, Dr. Stathakis has served as a peer reviewer for high-impact journals such as the Journal of Applied Clinical Medical Physics (JACMP), further highlighting his standing in the scientific community. He has also been recognized by institutions where he has taught and worked, receiving commendations for excellence in mentorship and clinical service. These honors reflect his consistent commitment to innovation, patient safety, and education, solidifying his reputation as a respected leader in medical physics and radiation oncology.

Publication Top Notes

  • AAPM TG report 312: Acceptance testing, commissioning, and periodic quality assurance of ion chamber and diode detector arrays — 2025

  • Dosimetric characterization of a new surface-conforming electron MLC prototype — 2024 — 1 citation

  • Monte Carlo modeling of the Elekta Versa HD and patient dose calculation with EGSnrc/BEAMnrc — 2022 — 5 citations

  • Erratum to: Report of AAPM Task Group 219 on independent calculation-based dose/MU verification for IMRT — 2021

  • Artificial intelligence based deconvolving on megavoltage photon beam profiles for radiotherapy applications — 2022

  • A customizable aluminum compensator system for total body irradiation — 2021

Conclusion

Dr. Sotirios Stathakis’s career represents a remarkable combination of academic excellence, clinical innovation, and professional leadership. His work has transformed multiple aspects of radiation oncology, from enhancing treatment planning accuracy to implementing robust quality assurance protocols that safeguard patient outcomes. With a strong foundation in education from top institutions across Canada, the United Kingdom, and Greece, coupled with his leadership roles in the United States, he exemplifies the global nature of medical physics. His research interests and skills reflect both scientific rigor and compassion, as he continually integrates patient-centered approaches into his innovations. Recognized internationally through awards, honors, and professional certifications, Dr. Stathakis has established himself as a trusted authority in his field. His mentorship of students and collaboration with clinicians ensure that his influence extends beyond his individual achievements, shaping the future of cancer care. Looking ahead, his engagement with artificial intelligence, wearable technology, and advanced radiotherapy models positions him to make further groundbreaking contributions. In sum, Dr. Stathakis embodies the qualities of a dedicated researcher, educator, and clinician, making him not only a leader in medical physics but also a driving force in advancing the fight against cancer globally.

Maria Kourti | Medicine and Dentistry | Best Researcher Award

Published on by Shen Awards

Prof. Maria Kourti | Medicine and Dentistry | Best Researcher Award

Aristotle University of Thessaloniki | Greece

Prof. Maria Kourti is a distinguished academic and medical professional specializing in Pediatrics with a particular focus on Pediatric Hematology, Oncology, and Infectious Diseases. She currently serves as an Assistant Professor at Aristotle University of Thessaloniki, where she has been deeply involved in both teaching and research. Her career spans over two decades of excellence in clinical practice, scientific research, and international collaborations, with significant contributions to the understanding of childhood leukemia, drug resistance mechanisms, and pediatric infectious diseases. She has authored 73 publications indexed in PubMed, holds an h-index of 16, and has received over 1,000 citations, making her a recognized figure in her field. Prof. Kourti has combined clinical expertise with cutting-edge molecular and proteomic research, actively leading and participating in international multicenter studies and clinical trials. She is also extensively engaged in professional societies at the European and global levels, serving as a board member and committee leader in organizations dedicated to pediatric health. Alongside her academic achievements, she has contributed to medical education, mentorship, and health promotion initiatives, underlining her holistic approach to advancing both science and society. Her distinguished record makes her a highly respected leader in pediatric research and medicine.

Professional Profile

Scopus | ORCID 

Education

Prof. Maria Kourti pursued her entire academic journey at the Aristotle University of Thessaloniki, Greece, one of the most prestigious institutions in the country. She obtained her Medical Degree, laying the foundation for her career in pediatrics. With a strong interest in scientific research, she further advanced her education by earning a Master of Science (MSc) in Medical Research Technology, where she developed early expertise in biomedical investigations. Her passion for oncology and molecular medicine culminated in her Ph.D, with her thesis focused on the “Study of expression of multi-drug resistance genes in pediatric leukemia,” a topic that remains central to her research today. Her commitment to academic and clinical growth did not stop there, as she pursued advanced medical specialization, becoming Board Certified as a Specialist Pediatrician and later recognized as a Pediatric Infectious Disease Specialist. In the same year, she also completed a Post-Doctoral Fellowship in Proteomics in Childhood Leukemia, marking her continued dedication to translational research. This progression highlights her unique integration of medicine and science, equipping her with the academic depth and clinical expertise to make pioneering contributions in pediatric hematology, oncology, and infectious diseases.

Professional Experience

Prof. Maria Kourti has held several critical roles in clinical practice and academia, reflecting her dual expertise as a physician and researcher. she served as an Attending Physician in the Pediatric Oncology Department at Hippokration General Hospital, where she gained extensive clinical experience in treating children with hematological malignancies and solid tumors. Her expertise further deepened during her Pediatric Infectious Disease Fellowship at Aristotle University of Thessaloniki, based at Hippokration General Hospital. she worked as an Attending Physician in the 3rd Department of Pediatrics at Aristotle University, responsible for managing the Pediatric Hematology Unit, demonstrating her leadership in both patient care and academic responsibilities. she was appointed Assistant Professor of Pediatrics–Pediatric Hematology and Oncology at Aristotle University of Thessaloniki, where she continues to combine clinical duties with teaching and high-level research. Her responsibilities extend beyond the university, as she actively participates in national and international research programs, leading initiatives on childhood cancer, supportive care, and clinical trials. Through these roles, Prof. Kourti has developed a reputation for clinical excellence, academic leadership, and research innovation, making her a central figure in pediatric hematology and oncology in Greece and abroad.

Research Interests

Prof. Kourti’s research interests span the intersection of molecular biology, pediatric oncology, and infectious diseases, with a strong emphasis on improving treatment outcomes for children with cancer. Her doctoral and postdoctoral work centered on the molecular mechanisms of drug resistance in childhood leukemia, specifically the expression of multi-drug resistance genes and the application of proteomics to understand disease progression and treatment response. She has also been deeply engaged in genetic polymorphism studies, particularly in metabolic enzymes of carcinogenic substances in patients with acute leukemias and myelodysplastic syndromes. In addition to her oncology work, she has pursued significant research in pediatric infectious diseases, coordinating national efforts for the Greek Supportive Care Group and contributing to clinical research on antifungal therapies and novel antimicrobial strategies. Her interests also extend to large-scale clinical collaborations, where she has been both principal and sub-investigator in 15 multinational clinical trials addressing treatments for pediatric cancers and infections. This breadth of research demonstrates her commitment to translational medicine, bridging laboratory research with clinical applications. Her interests align with global health priorities, focusing on improving survival, reducing treatment toxicity, and enhancing supportive care in children with cancer.

Research Skills

Prof. Kourti possesses a strong foundation in molecular biology and clinical research methodologies, supported by advanced training and decades of practical application. Her technical expertise includes DNA and RNA extraction from blood and bone marrow samples, agarose gel electrophoresis, PCR, and RT-PCR, enabling her to investigate genetic and proteomic markers in pediatric leukemia. She has extensive experience with clinical trial design and implementation, having served as both a principal investigator and sub-investigator in numerous international studies, particularly within the SIOPE and SIOPEN networks. Her skills also extend to multidisciplinary collaboration, coordinating research teams across clinical and laboratory settings. In addition, Prof. Kourti has developed editorial and peer-review skills through her role as Guest Editor of special issues in international journals such as the Journal of Fungi and Diagnostics and as a reviewer for more than 10 medical journals. She also demonstrates expertise in data interpretation, publication writing, and conference presentation, with over 100 oral and poster presentations at national and international congresses. Her combined clinical and laboratory research skills, along with her organizational and editorial experience, make her a versatile and influential contributor to pediatric oncology and infectious disease research worldwide.

Awards and Honors

Throughout her career, Prof. Maria Kourti has received numerous awards and honors recognizing her excellence in research, teaching, and clinical practice. She has earned 10 major distinctions, including 3 scholarships from the National Scholarship Foundation (IKY), awarded for her academic performance and research potential. In addition, she has received 3 educational grants supporting her clinical and research training, as well as 6 first prizes for oral and poster presentations at both national and international medical congresses. These awards highlight not only her dedication to scientific inquiry but also her ability to effectively communicate her findings to diverse audiences. Beyond individual recognition, her leadership roles within professional societies such as the Hellenic Society for Social Pediatrics and Health Promotion, the National Pediatric Hematology and Oncology Society, and participation in European cooperative groups (SIOPE, ESPID, EXPeRT, ESCMID) further demonstrate the esteem in which she is held by the medical and scientific community. She has also contributed as a committee member for sustainability at ESPID, reflecting her commitment to long-term scientific advancement and ethical research practices. These honors collectively underscore her outstanding achievements and her influential role in pediatric medicine and research.

Publication Top Notes

  • Antifungal Use in Immunocompromised Children in Europe: A 12-Week Multicenter Weekly Point Prevalence Survey (CALYPSO) — 2025

  • A Global Analysis of Cases of Mucormycosis Recorded in the ECMM / ISHAM Zygomyco.net Registry from 2009 to 2022 — 2025

  • Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Research Network — 2025 — 3 citations

  • Addressing infectious challenges in pediatric cancer and hematopoietic cell transplantation: insights from the Umbrella Working Group — 2025

  • Invasive Fungal Disease After Chimeric Antigen Receptor-T Immunotherapy in Adult and Pediatric Patients — 2025

  • Planetary Health: What You Need to Know as a Pediatric Infectious Diseases Doctor — 2025

  • Successful Treatment of Disseminated Fusariosis in a 15-Month-old Boy With Refractory Acute Lymphoblastic Leukemia Using High-dose Voriconazole — 2024 — 1 citation

  • Usage of Antifungal Agents in Pediatric Patients Versus Adults: Knowledge and Gaps — 2025

Conclusion

Prof. Maria Kourti exemplifies the qualities of a leading physician-scientist, with a career that integrates clinical expertise, innovative research, and academic leadership. Her groundbreaking work in childhood leukemia, infectious diseases, and pediatric oncology has advanced both scientific knowledge and clinical practice, directly impacting patient outcomes. With more than 73 peer-reviewed publications, extensive participation in international clinical trials, and leadership in national and European research groups, she has established herself as a key figure in the global pediatric research community. Her commitment to mentoring young scientists, active involvement in health promotion initiatives, and editorial contributions further enhance her academic profile. Looking ahead, Prof. Kourti is well-positioned to expand her research into global collaborations, increase her presence in high-impact journals, and take on greater leadership roles in shaping international pediatric oncology policies. Her career trajectory reflects not only past accomplishments but also significant potential for future contributions to medicine, making her a highly deserving candidate for continued recognition. In summary, Prof. Kourti’s lifelong dedication to advancing pediatric care and medical science positions her as an outstanding role model and leader in the field.

Pedro Antonio Regidor | Medicine and Dentistry | Best Researcher Award

Published on by Shen Awards

Dr. Pedro Antonio Regidor | Medicine and Dentistry | Best Researcher Award

Medical Director from Exeltis Healthcare | Germany 

Dr. Pedro Antonio Regidor is a dual-national (Spanish and German) medical doctor and scientist with over three decades of clinical and leadership experience in the field of gynecology and obstetrics. He is currently the Medical Director of Exeltis Europe & Global Projects, overseeing pharmaceutical initiatives and innovations in women’s health across international markets. Dr. Regidor is a specialist in gynecological oncology, reproductive medicine, surgical gynecology, and perinatal care, and has performed thousands of complex surgeries and deliveries. His clinical expertise is reinforced by his academic contributions, having earned an MD in 1992 and a PhD in 2000 from the University of Essen. He has held several key roles in prominent German institutions such as the University of Essen, Westfälische Wilhelms-Universität Münster, and Klinikum Osnabrück. In addition, he has served in leadership roles within private medical consultancies and pharmaceutical companies. Dr. Regidor’s career reflects a dynamic integration of patient care, medical research, academic excellence, and corporate strategy. Through his work with Exeltis and affiliations with multiple scientific boards, he continues to shape the future of gynecological healthcare and pharmaceutical development on a global scale.

Professional Profile

Scopus Profile | ORCID Profile

Education

Dr. Regidor’s academic foundation is built on a robust medical and scientific education acquired in Germany. He earned his Doctor of Medicine (MD) on 21 March 1992, with a thesis focused on immunohistochemical detection of progesterone receptors in various tissues. His pursuit of advanced knowledge continued with a PhD in Gynecology and Obstetrics awarded by the University of Essen on 14 April 2000, based on research into peritoneal endometriosis. His studies not only demonstrated academic excellence but also provided the groundwork for his specializations in women’s health. Throughout his educational journey, he gained comprehensive training in multiple sub-disciplines, including endocrine disorders, surgical gynecology, and diagnostic imaging techniques such as mammography and hysterosalpingography. Dr. Regidor also pursued professional licensure in multiple countries, including Germany and Switzerland, reflecting his global perspective and adaptability in medical practice. He earned several professional qualifications between 1995 and 2006, officially recognized as a specialist in gynecology and obstetrics, gynecological endocrinology, reproductive medicine, and gynecological oncology. His academic credentials have empowered him to lead not only in clinical settings but also in the pharmaceutical and medical research sectors, demonstrating a lifelong commitment to education and advancement in medical science.

Professional Experience

Dr. Pedro Antonio Regidor has accumulated over 30 years of diverse professional experience, ranging from university hospitals and private clinics to high-level executive roles in the pharmaceutical industry. He began his medical career as a junior and medical resident at the University of Essen, focusing on gynecological oncology. His international exposure included a residency at Clínica Maternidad Concepción Palacios in Caracas, Venezuela, which enriched his global medical perspective. He later served as Assistant Medical Director in Essen and at Westfälische Wilhelms-Universität Münster, eventually becoming Chief of the Department of Gynecology and Obstetrics at Klinikum Osnabrück. Following years of leading hospital-based services, Dr. Regidor transitioned into private consultancy and pharmaceutical leadership roles. Since 2009, he has been affiliated with Frauenklinik München West and worked in executive medical roles for Velvian Germany GmbH and Exeltis. Currently, he is Medical Director of Exeltis Europe & Global Projects, managing international clinical and product development strategies. His career is distinguished by thousands of complex surgeries, strategic oversight of medical centers, and leadership in multinational pharmaceutical operations. His ability to bridge clinical knowledge with organizational leadership makes him a rare expert in both hands-on patient care and large-scale medical innovation.

Research Interests

Dr. Regidor’s research interests lie primarily in gynecological oncology, reproductive medicine, endocrinology, and women’s health diagnostics and therapeutics. He has a strong academic inclination toward understanding the pathophysiology of endometriosis, as evidenced by his PhD research on immunohistochemical investigations. He is particularly focused on the integration of clinical evidence with pharmacological innovation, developing solutions that address unmet needs in hormone replacement therapy, fertility regulation, and perinatal management. Through his leadership at Exeltis, he also explores new formulations of estrogen and progesterone therapies, especially in menopausal care and contraceptive technologies. Dr. Regidor is deeply invested in the development and validation of clinical protocols for surgical interventions, breast reconstruction, hormone diagnostics, and cancer therapy. He continues to engage in international collaborative research projects, particularly in clinical trials involving women’s hormone treatments and breast cancer. Additionally, he serves on scientific boards and advisory committees that drive research agendas in reproductive endocrinology and gynecological oncology. His work frequently intersects clinical application with scientific innovation, making him a key figure in translational medicine.

Research Skills

Dr. Regidor possesses a highly specialized skill set that encompasses both clinical research and surgical expertise. He is proficient in conducting immunohistochemical analyses, clinical trial coordination, and protocol development. His strong foundation in gynecological diagnostics allows him to interpret laboratory results with precision and apply them directly in surgical and medical decision-making. His surgical record is extensive, with over 7,000 procedures ranging from total laparoscopic hysterectomies to breast reconstructions, demonstrating exceptional hands-on expertise. In research contexts, he is adept at designing clinical studies, interpreting biomedical data, and ensuring ethical compliance across international sites. He has a deep understanding of hormonal pathways, disease modeling, and advanced imaging techniques, including radiological diagnostics for gynecologic applications. Dr. Regidor is also skilled in multilingual communication, enabling him to effectively collaborate on global research initiatives. Furthermore, his involvement with pharmaceutical companies has honed his abilities in regulatory science, medical writing, and strategic development of therapeutic pipelines. His combined skills in surgery, diagnostics, and clinical research make him a versatile asset in both academic and industry settings.

Awards and Honors

Over the course of his distinguished career, Dr. Pedro-Antonio Regidor has received numerous appointments and recognitions reflective of his impact in gynecology and medical leadership. While his career is not defined by traditional academic awards, his leadership roles themselves signify recognition by his peers and institutions. He served as Coordinator and Founding Member of the Breast Center in Münster, a pioneering initiative that contributed to Germany’s breast cancer diagnostic network. His repeated appointments as Medical Director at Velvian Germany GmbH and Exeltis Germany, Europe, and Global Projects further underscore his reputation as a trusted leader in the medical and pharmaceutical sectors. Additionally, he has been entrusted with consultancy roles for companies like Lipocine Inc. (USA) in the field of hormone therapy, showcasing global acknowledgment of his expertise. He holds membership in over ten professional societies, including the German Society for Gynecology and Obstetrics, West German Tumor Center, and scientific advisory boards related to endometriosis and reconstructive surgery. These positions not only validate his contributions but also recognize his ability to drive forward scientific agendas with clinical relevance.

Publications Top Notes

  • Effect over coagulation and fibrinolysis parameters of a prolonged-release contraceptive (2025) – Gynecological Endocrinology – 1 citation.

  • Prevalence of cumulative cardiovascular risk factors among French women of childbearing age: GYNRISK® survey (2025) – Journal of Gynecology Obstetrics and Human Reproduction – 1 citation.

  • Randomised trial comparing bleeding profiles of prolonged vs immediate-release contraceptives (2025) – European Journal of Contraception and Reproductive Health Care – 3 citations.

  • Anti-inflammatory effects of marine oil enriched with SPMs in Post-COVID Syndrome patients (2024) – Biomedicines – 4 citations.

  • Marine oil supplements during pregnancy to prevent preterm delivery (Review).

  • Omega-3 fatty acids and their role in pregnancy complications like preeclampsia and chorioamnionitis (Review)

Conclusion

Dr. Pedro-Antonio Regidor stands out as a multifaceted leader in gynecology, medical research, and pharmaceutical innovation. His extensive clinical experience, combined with a strong academic foundation and strategic leadership in the pharmaceutical industry, positions him uniquely at the intersection of science and healthcare delivery. He has made significant contributions to women’s health through his pioneering surgical interventions, research in reproductive medicine, and development of hormone-based therapies. His roles in clinical practice, academia, and corporate governance reflect a deep commitment to advancing medical science and improving patient care. Dr. Regidor’s work has positively impacted thousands of patients and influenced the direction of therapeutic innovation across Europe and beyond. With ongoing involvement in global projects and advisory boards, he is poised to further shape the landscape of gynecological healthcare and translational research. His career exemplifies excellence, leadership, and a tireless pursuit of medical advancement, making him a highly deserving candidate for recognition in international research and medical awards.

Kazutomo Sawai | Health Professions | Best Researcher Award

Published on by Shen Awards

Dr. Kazutomo Sawai | Health Professions | Best Researcher Award

President from Hanshin Medical Co-op Daisan Clinic, Japan

Dr. Kazutomo Sawai is a distinguished Japanese physician-researcher specializing in nephrology and Kampo (traditional Japanese) medicine. He has made outstanding contributions to the understanding of glomerular regeneration, diabetic nephropathy, and molecular markers of kidney disease. With over two decades of clinical and research experience, Dr. Sawai combines modern medical science with traditional therapeutic approaches to address complex renal pathologies. His professional journey encompasses high-level academic training, fellowships at prominent institutions, and leadership roles within clinical practice and education. Since 2010, he has served as President of Daisan Clinic in Amagasaki, Hyogo, Japan, where he also champions patient education and community healthcare. Dr. Sawai’s international presence is marked by presentations at global nephrology congresses, highlighting his pivotal research on Connexin43 and Cyr61 expression in diabetic nephropathy and glomerulonephritis. His clinical insights are further enriched through his integration of Kampo medicine, reflected in his successful management of chronic cases through traditional prescriptions. A fellow of multiple Japanese medical societies, he has received notable honors for his scientific achievements. Dr. Sawai remains a committed clinician, educator, and researcher, dedicated to translational nephrology, patient-centered care, and the advancement of integrative medicine practices.

Professional Profile

Education

Dr. Kazutomo Sawai pursued his foundational medical education at the esteemed Kyoto University School of Medicine, obtaining his M.D. in 1995. Demonstrating an early interest in renal pathophysiology, he continued his academic journey by earning a Ph.D. in Renal Physiology from Kyoto University Graduate School of Medicine in 2004. His doctoral work focused on glomerular disease mechanisms and the role of angiogenic and podocyte-specific factors in kidney regeneration. Dr. Sawai’s postgraduate training included a comprehensive residency in internal medicine at Kyoto University Hospital and Saiseikai Nakatsu Hospital between 1995 and 1997. He later undertook specialized fellowships in nephrology and dialysis therapy from 1998 to 2001 at both Saiseikai Nakatsu and Kyoto University Hospitals. Expanding his scope beyond conventional medicine, Dr. Sawai completed dual fellowships in Kampo medicine between 2015 and 2018 at Midorinokaze Clinic and Rakuwakai Otowa Hospital. This diverse academic and clinical training underpins his multidisciplinary approach to kidney care, integrating Western biomedical science with traditional Japanese therapeutics. Dr. Sawai’s strong academic background has laid a robust foundation for his research contributions and clinical leadership, positioning him as a key figure in the evolution of nephrology and holistic patient care in Japan.

Professional Experience

Dr. Sawai has cultivated an illustrious professional career marked by significant academic, clinical, and administrative roles. His early medical career began with residencies in internal medicine at Kyoto University Hospital and Saiseikai Nakatsu Hospital from 1995 to 1997. He then specialized in nephrology and dialysis therapy during fellowships at these institutions through 2001. Dr. Sawai’s academic appointments include a role as Project Researcher in Internal Medicine at Kyoto University in 2004 and a notable tenure as Chief Researcher at the National Cardiovascular Center Research Institute in Osaka from 2004 to 2010. In 2010, he assumed the presidency of Daisan Clinic in Amagasaki, where he continues to practice, lead, and mentor. His responsibilities extend to community health, serving as Medical Director and Adviser for local home care services, and contributing as a committee member overseeing free and low-cost medical programs. He has also taught at Saiseikai Nakatsu Nursing School and Hanshin Cooperative Association Community College. With an integrated focus on internal medicine, nephrology, dialysis, and Kampo medicine, Dr. Sawai’s professional journey reflects a commitment to advancing holistic healthcare, clinical education, and community outreach.

Research Interest

Dr. Sawai’s research interests span the molecular, cellular, and clinical dimensions of nephrology. His work is particularly focused on the pathophysiology of glomerular diseases, including diabetic nephropathy, anti-GBM nephritis, and glomerulonephritis. He has extensively investigated the roles of podocyte-specific genes, such as Cyr61 (CCN1) and Connexin43, in renal injury and regeneration. These studies have led to insights into the mechanisms of podocyte dysfunction and the potential use of angiogenic and regenerative factors in predicting or improving renal outcomes. A pioneer in integrating traditional medicine into modern nephrology, Dr. Sawai has also explored the therapeutic applications of Kampo prescriptions in managing chronic symptoms such as dementia, hypertension, and neuropathic pain. His case studies highlight the efficacy of herbal formulations in complex clinical scenarios that often resist conventional treatment. His broader interest encompasses translational nephrology, where laboratory discoveries can inform clinical practice. With a comprehensive understanding of both biomedical science and traditional Japanese healing systems, Dr. Sawai’s research bridges disciplines to deliver patient-centered, evidence-based, and integrative kidney care. His continuous presence at national and international conferences further demonstrates his commitment to advancing nephrology and promoting the fusion of traditional and modern medical systems.

Research Skills

Dr. Sawai brings a sophisticated portfolio of research skills to the field of nephrology and integrative medicine. Trained in both clinical and bench research environments, he has demonstrated strong capabilities in experimental nephrology, molecular biology, and pathophysiological analysis. His core competencies include immunohistochemistry, gene expression profiling, and biomarker discovery, particularly focusing on proteins like Cyr61 and Connexin43 in renal pathology. His collaborative research has leveraged rodent models of glomerulonephritis and diabetic nephropathy to explore regeneration pathways in the kidney. Dr. Sawai’s ability to translate these findings into clinical insights distinguishes his work in translational medicine. Additionally, his skills extend to clinical trial design, retrospective case analysis, and Kampo prescription efficacy assessment, making him a rare blend of experimental and clinical researcher. He is also an experienced academic presenter and has delivered over 30 presentations at regional, national, and international conferences. His capacity for multidisciplinary collaboration, particularly in combining conventional nephrology with traditional Japanese Kampo medicine, reflects advanced integrative research skills. Through his leadership at Daisan Clinic, he continues to apply these skills in real-world settings, facilitating a seamless interface between research innovation and patient care.

Awards and Honors

Throughout his career, Dr. Kazutomo Sawai has received multiple accolades in recognition of his academic and research excellence. Among the earliest distinctions was the Miyake Memorial Award from Kyoto University Graduate School of Medicine in 2003, acknowledging his contributions to internal medicine and clinical science. In 2004, he was the recipient of the Tsujisaka Memorial Scholarship, awarded for scholarly promise and research potential in the field of renal physiology. The Young Researcher’s Award conferred at the 42nd Annual Meeting of the Japanese Society of Molecular Medicine in 2005 further highlighted his innovative work on glomerular regeneration. He also earned a Travel Grant from the American Society of Nephrology, which enabled him to present his research at international platforms and expand cross-border academic exchange. These honors not only affirm his impactful scientific work but also emphasize his contributions to the global discourse on nephrology. Dr. Sawai’s recognition by both Japanese and international institutions reflects the high quality and significance of his research. His continued academic output and interdisciplinary approach ensure that he remains at the forefront of innovation in renal medicine and integrative therapies.

Conclusion

Dr. Kazutomo Sawai stands out as a clinician-researcher of exceptional caliber, whose multifaceted career bridges the realms of nephrology, internal medicine, and Kampo therapeutics. His academic foundation at Kyoto University, combined with specialized fellowships in nephrology and traditional medicine, has shaped a unique professional identity that is both modern and rooted in tradition. As President of Daisan Clinic, he has made significant contributions to clinical nephrology while also enhancing community health services and medical education. Dr. Sawai’s research has had a profound impact on the understanding of podocyte biology, glomerular regeneration, and diabetic nephropathy, with practical applications for improving patient outcomes. His pioneering integration of Kampo medicine into nephrology offers novel approaches to managing chronic, treatment-resistant conditions. Despite a lack of editorial roles, his active participation in national and international scientific forums and multiple honors confirm his standing in the field. Dr. Sawai exemplifies dedication to science, education, and compassionate patient care, making him an ideal candidate for prestigious recognition such as the Best Researcher Award. His work continues to inspire the next generation of healthcare professionals and researchers in Japan and beyond.

Publications Top Notes

1. Traditional remedy-induced Chinese herbs nephropathy showing rapid deterioration of renal function

  • Year: 1997

  • Authors: Tanaka A, Nishida R, Sawai K, Nagae T, Shinkai S, Ishikawa M, Maeda K, Murata M, Seta K, Okuda J, Yoshida T, Sugawara A, Kuwahara T

  • Journal: Nihon Jinzo Gakkai Shi

2. Human parvovirus B19 infection resembling systemic lupus erythematosus

  • Year: 1998

  • Authors: Tanaka A, Sugawara A, Sawai K, Kuwahara T

  • Journal: Intern Med

3. Concealed hypothyroidism in patients with myeloperoxidase antineutrophil cytoplasmic autoantibodies (MPO-ANCA) positive renal disease

  • Year: 1999

  • Authors: Tanaka A, Maeda K, Sawai K, Okuda J, Sugawara A, Kuwahara T

  • Journal: Clinical Nephrology

4. Intraglomerular metastasis from pancreatic cancer

  • Year: 2001

  • Authors: Yokoi H, Nakata M, Sawai K, Yoshida T, Koshikawa M, Joyama S, Tanaka A, Goto M, Ueda S, Senzaki H, Sugawara A, Kuwahara T

  • Journal: American Journal of Kidney Diseases

5. C4d and C4bp deposition along the glomerular capillary walls in a patient with preeclampsia

  • Year: 2001

  • Authors: Joyama S, Yoshida T, Koshikawa M, Sawai K, Yokoi H, Tanaka A, Gotoh M, Ueda S, Sugawara A, Kuwahara T

  • Journal: American Journal of Kidney Diseases

6. Angiogenic protein Cyr61 is expressed by podocytes in anti-Thy-1 glomerulonephritis

  • Year: 2003

  • Authors: Sawai K, Mori K, Mukoyama M, Sugawara A, Suganami T, Koshikawa M, Yahata K, Makino H, Nagae T, Fujinaga Y, Yokoi H, Yoshioka T, Yoshimoto A, Tanaka I, Nakao K

  • Journal: Journal of the American Society of Nephrology

7. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis

  • Year: 2004

  • Authors: Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K, Yoshioka T, Koshikawa M, Nishida T, Takigawa M, Sugawara A, Nakao K

  • Journal: Journal of the American Society of Nephrology

8. Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy

  • Year: 2005

  • Authors: Suganami T, Mukoyama M, Mori K, Yokoi H, Koshikawa M, Sawai K, Hidaka S, Ebihara K, Tanaka T, Sugawara A, Kawachi H, Vinson C, Ogawa Y, Nakao K

  • Journal: FASEB Journal

9. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury

  • Year: 2005

  • Authors: Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM, Chen X, Li JY, Weiss S, Mishra J, Cheema FH, Markowitz G, Suganami T, Sawai K, Mukoyama M, Kunis C, D’Agati V, Devarajan P, Barasch J

  • Journal: Journal of Clinical Investigation

10. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome

  • Year: 2005

  • Authors: Koshikawa M, Mukoyama M, Mori K, Suganami T, Sawai K, Yoshioka T, Nagae T, Yokoi H, Kawachi H, Shimizu F, Sugawara A, Nakao K

  • Journal: Journal of the American Society of Nephrology

Zachariah Chowdhury | Medicine and Dentistry | Best Researcher Award

Published on by Shen Awards

Dr. Zachariah Chowdhury | Medicine and Dentistry | Best Researcher Award

Professor, Dept Of Oncopathology from Mahamana Pandit Madan Mohan Malviya Cancer Centre (Tata Memorial Hospital) Varanasi, India

Dr. Zachariah Chowdhury is an accomplished academician, clinician, and researcher in the field of oncopathology, currently serving as the Professor and Officer-in-Charge of the Department of OncoPathology at the Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMMCC) & Homi Bhabha Cancer Hospital (HBCH) in Varanasi, under the Tata Memorial Centre. With foundational training in MBBS and MD in Pathology from Assam Medical College and a UICC Fellowship in Oncopathology, he has demonstrated an unwavering commitment to excellence in pathology and cancer diagnostics. His extensive teaching background includes instruction at multiple academic levels, including DM, MD, MBBS, nursing, and laboratory technology programs. Dr. Chowdhury has amassed an impressive portfolio of over 50 peer-reviewed publications, addressing both common and rare oncological conditions, contributing significantly to the evolving understanding of oncopathology. He is recognized for his comprehensive approach that merges histopathology, cytopathology, hematopathology, and molecular pathology. As a reviewer, invited speaker, and research presenter at both national and international platforms, he exemplifies the qualities of a dedicated and visionary medical researcher. His contributions to both clinical practice and research make him a pivotal figure in the Indian medical community and a strong candidate for national and international honors in the field of cancer pathology.

Professional Profile

Education

Dr. Chowdhury’s academic journey began with outstanding scholastic achievements, securing the 5th rank in his Higher Secondary School Examination from Cotton College, Guwahati, with a remarkable 83.6% score. He earned his MBBS from Assam Medical College under Dibrugarh University in 2004, ranking 2nd in his final examinations. His dedication to medical sciences continued with an MD in Pathology in 2011 from the same institution, where he again demonstrated academic excellence by clearing all examinations in his first attempt. Complementing his postgraduate training, Dr. Chowdhury was awarded the prestigious UICC/Dr. Praful Desai Fellowship in Oncopathology at Tata Memorial Centre, Mumbai, where he further honed his expertise in histopathology, cytopathology, and molecular diagnostics. Additionally, he underwent advanced training in molecular pathology at Tata Medical Centre, Kolkata, and Tata Memorial Centre, Parel, reinforcing his foundation in modern cancer diagnostics. His academic credentials are supported by multiple merit certificates from the Assam Higher Secondary Education Council, All Assam Students Union, and Assam Medical College, highlighting consistent academic distinction from secondary education through to his postgraduate years. This strong educational foundation has enabled Dr. Chowdhury to effectively lead both clinical and academic responsibilities in the field of oncopathology.

Professional Experience

Dr. Zachariah Chowdhury has accumulated rich and diverse professional experience across multiple prestigious institutions. He began his teaching career as a Senior Resident Doctor at the North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS), Shillong, where he served for three years post-MD, laying a strong foundation in clinical pathology and academic instruction. Currently, he serves as Professor and Officer-in-Charge of the Department of OncoPathology at MPMMCC & HBCH in Varanasi, both units under the Tata Memorial Centre. In this leadership role, he oversees academic training and diagnostic services in a high-volume cancer care setting. Dr. Chowdhury’s responsibilities include teaching DM (OncoPathology), MD (Pathology), MBBS, nursing, and laboratory science students in both theory and laboratory environments. His clinical expertise encompasses a wide spectrum, including histopathology, cytopathology, hematopathology, molecular diagnostics, clinical pathology, renal pathology, immunopathology, and blood banking. Additionally, he plays an active role in quality assurance programs within the diagnostic laboratory. Beyond his hospital commitments, he contributes to academia as a peer reviewer for multiple reputed medical journals and participates in national and international conferences as a speaker, panelist, and faculty. This blend of academic, clinical, and leadership experience underscores his stature as a seasoned medical professional.

Research Interest

Dr. Chowdhury’s research interests center around oncopathology with a multidisciplinary focus that integrates histopathology, molecular pathology, cytopathology, and hematopathology. His scholarly work investigates a wide range of oncological conditions, including breast cancer, thyroid lesions, ovarian tumors, pediatric malignancies, head and neck cancers, and hematolymphoid neoplasms. A key area of his research explores the diagnostic challenges and spectrum of rare tumors such as salivary gland neoplasms, solitary fibrous tumors, and angiosarcomas, with a special emphasis on cytohistological correlations and immunomorphological profiling. Additionally, he has contributed to understanding emerging themes like artificial intelligence in histopathology and the role of molecular diagnostics in rare malignancies. His recent studies include real-world clinical data on metastatic cancers and chemotherapy outcomes, bridging clinical practice with diagnostic research. Dr. Chowdhury’s commitment to evidence-based pathology is evident in his methodical approach to publishing both retrospective reviews and case-based literature, offering valuable insights to the global oncopathology community. His collaborations with multidisciplinary teams from oncology, radiology, and surgery reflect his integrative research philosophy. By focusing on both common diagnostic patterns and rare, underreported entities, his work not only advances academic pathology but also significantly contributes to clinical decision-making and patient outcomes.

Research Skills

Dr. Zachariah Chowdhury brings to the research landscape a comprehensive skill set encompassing classical and modern pathology techniques. He is proficient in histological examination, cytopathological evaluations (including FNAC and core biopsies), hematopathology analyses, and cutting-edge molecular diagnostics. His training at leading cancer centers like Tata Memorial Centre and Tata Medical Centre has equipped him with practical expertise in PCR, FISH, and immunohistochemistry techniques—essential tools in the molecular characterization of tumors. He also has expertise in immunomorphology and has applied these skills across a broad range of clinical cases, from pediatric cancers to high-grade lymphomas and soft tissue tumors. Dr. Chowdhury is also skilled in academic writing and statistical analysis, as evidenced by his extensive publication record across peer-reviewed indexed journals. His systematic approach to clinical audits, retrospective analyses, and diagnostic algorithm development further highlight his research rigor. Additionally, he has contributed to AI applications in cancer diagnosis, showcasing adaptability to new technologies. His experience in organizing research presentations and mentoring junior faculty and students also reflects strong leadership and team management skills within research settings. Altogether, his multidimensional research skills strongly align with the goals of translational oncology and precision medicine.

Awards and Honors

Dr. Chowdhury’s illustrious career has been recognized with numerous awards and honors, validating his significant impact in the field of pathology. Among the most notable are the Bharat Gaurav Puraskar (2023) and the Jewel of India Award (2024), both conferred by the KTK Outstanding Achievers and Education Foundation, New Delhi, for his exemplary contributions to pathology and medical education. During his academic years, he received multiple certificates of merit for academic excellence, including top ranks in both secondary and medical school examinations. His postgraduate performance earned him a Certificate of Merit from Assam Medical College. As a faculty member and researcher, he has consistently excelled in academic events, winning the first prize in Oral Paper Presentation at the 5th International Pediatric Pathology Conference (2022) and the Poster Presentation at NEIGRIHMS Annual Research Day (2018). His early career awards also include the North Eastern Council (NEC) Scholarship for MBBS, which supported his foundational medical education. Beyond these, his recognition extends to being a respected reviewer for multiple journals, and his frequent roles as invited speaker and panelist at various conferences. These accolades reflect both peer and institutional acknowledgment of his enduring impact on medical research and education.

Conclusion

Dr. Zachariah Chowdhury exemplifies the ideals of a clinician-scientist dedicated to excellence in oncopathology. With a firm grounding in both classical pathology and modern diagnostic innovations, he bridges the gap between histological diagnosis and translational cancer research. His career reflects a rare combination of clinical acumen, academic mentorship, research productivity, and institutional leadership. Through his prolific authorship of over 50 peer-reviewed publications, he contributes actively to the global understanding of complex and rare oncological entities. His commitment to education is evident in his multi-level teaching engagements and ongoing mentorship of pathology trainees. Dr. Chowdhury’s recognition through multiple national honors and academic awards further substantiates his role as a leading figure in cancer pathology in India. While already operating at a high level of academic and clinical distinction, future initiatives such as enhanced international collaborations, grant-funded research, and patent development would elevate his profile even further. Overall, Dr. Chowdhury represents a distinguished and highly qualified candidate for any recognition aimed at honoring pathologists and researchers who make substantial contributions to medical science, and particularly, to the evolving discipline of oncopathology.

Publications Top Notes

1. The many faces of ovarian sex cord stromal tumors: a clinicopathological analysis at a tertiary cancer center in North India

  • Year: 2025

  • Authors: Chowdhury Z, Agrawal S, Gupta S, Rai S, Jethani R, Saha S, Ranjan R, Pal A

  • Journal: Surgical and Experimental Pathology

2. The Myriad Spectrum of Salivary Gland Lesions: Cytohistological Correlation on Fine Needle Aspiration Cytology, Core Needle Biopsy, and Resections in a 5-Year Single Institutional Experience of North India

  • Year: 2025

  • Authors: Chowdhury Z, Majumdar P, Narain S, Lamba K

  • Journal: Diagnostic Cytopathology

3. ALK-positive large B-cell lymphoma: A study of six cases from an oncopathology center in North India

  • Year: 2025

  • Authors: Verma A, Chowdhury Z, Singh A, Kant A, Yadav A, Patne SCU

  • Journal: Indian Journal of Pathology and Microbiology

4. Cyto-Histomorphological Analysis of Thyroid Lesions and Risk Assessment of Malignancy/Neoplasia: Insights from a North Indian Tertiary Oncology Center

  • Year: 2025

  • Authors: Haiyat S, Chowdhury Z, Rudra Pal P, Patne S, Dhal I, Paul P

  • Journal: Cureus

5. An Analysis of Pediatric Round Cell Tumors Highlighting the Spectrum of Differential Diagnosis – A Single Center Experience and Systematic Review of Literature

  • Year: 2025

  • Authors: Dhal I, Lali BS, Rai H, Chowdhury Z, Patne S, Tripathi P, Saha S

  • Journal: International Journal of Scientific Studies

6. Real-world data on trastuzumab emtansine (TDM1) efficacy and safety: Results of a single-centre retrospective study of HER2-positive metastatic breast cancer patients

  • Year: 2025

  • Authors: Gupta A, Sansar B, Mishra BK, Khan A, Singh A, Upadhyay A, Chowdhury Z, Patne S, Tripathi M, et al.

  • Journal: Scientific Reports

7. Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study)

  • Year: 2025

  • Authors: Kapoor A, Gupta A, Sansar B, Mishra BK, Gupta P, Singh A, Upadhyay A, Kashyap L, Pal A, Kumar A, Nanda SS, Mukherji A, Kapoor AR, Pradhan S, Mishra A, Chowdhury Z, Patne S, Dhal I, Singh N, et al.

  • Journal: JCO Global Oncology

8. Exploring Solitary Fibrous Tumors at a Tertiary Cancer Center: Clinicopathological and Immunomorphologic Profile

  • Year: 2024

  • Authors: Chowdhury Z, Mishrikotkar S, Nehra P, Patne S, Tripathi M

  • Journal: Cureus

9. A Review of the Applications of Artificial Intelligence in Histopathology

  • Year: 2024

  • Authors: Kandarpa S, Chowdhury Z, Pal PR, Rajput K, Saraf SA

  • Journal: Journal of Cancer Research Reviews & Reports

10. Outcomes of De Novo Oligometastatic Breast Cancer Treated With Surgery of Primary and Metastasis Directed Radiotherapy

  • Year: 2024

  • Authors: Pujari L, Suresh A, Chowdhury Z, Pradhan S, Tripathi M, Gupta A, Singh P, Giridhar P, Kapoor AR, Shinghal A, Sansar B, Mv M

  • Journal: American Journal of Clinical Oncology

 

Nobuhiro Takahashi | Medicine and Dentistry | Best Researcher Award

Published on by Shen Awards

Dr. Nobuhiro Takahashi | Medicine and Dentistry | Best Researcher Award

Dermatologist from Tokai University School of Medicine, Japan

Dr. Nobuhiro Takahashi is a dedicated clinical professional specializing in dermatology, with a primary focus on inflammatory skin diseases. Currently serving as a Clinical Assistant in the Department of Dermatology at Tokai University Hospital, Kanagawa, Japan, Dr. Takahashi actively participates in both clinical practice and academic training. He has demonstrated a strong commitment to advancing patient care in outpatient dermatology. His work reflects a growing interest in combining clinical insights with research opportunities. With a solid foundation in medical education and practical experience, Dr. Takahashi shows promise for contributing significantly to dermatological research in the future.

Professional Profile

Education

Dr. Nobuhiro Takahashi completed his medical degree at Tokai University School of Medicine, Japan, graduating in March 2020. His academic training provided him with a comprehensive understanding of medical sciences, with a particular interest in dermatology developing during his studies. The rigorous curriculum at Tokai University laid the groundwork for his clinical reasoning, diagnostic skills, and patient management techniques. His education emphasized both theoretical knowledge and practical application, preparing him effectively for postgraduate clinical training and his current clinical role. Dr. Takahashi’s education continues to support his professional development and potential future contributions to clinical research.

Professional Experience

Dr. Takahashi began his professional journey as a Clinical Resident at Tokai University Hospital, where he completed a two-year postgraduate clinical training program from April 2020 to March 2022. This experience allowed him to build strong diagnostic and treatment skills across multiple medical disciplines. Since April 2022, he has been serving as a Clinical Assistant in the Department of Dermatology at Tokai University. In this role, he focuses on outpatient clinical dermatology and academic training, working closely with specialists to manage a variety of dermatological conditions. His current responsibilities allow him to blend clinical service with ongoing professional growth.

Research Interest

Dr. Takahashi’s primary research interests center around dermatology, particularly the study and management of inflammatory skin diseases. He is focused on improving clinical outcomes and advancing therapeutic strategies for these complex skin conditions. His exposure to diverse patient cases in an outpatient setting provides valuable clinical observations that can guide his research direction. While his current profile does not extensively detail research projects or publications, his interest in bridging clinical practice with academic research is evident. Dr. Takahashi is well-positioned to contribute to future dermatological studies that address common and challenging skin disorders.

Research Skills

Dr. Takahashi has developed a strong set of clinical and observational skills through his extensive outpatient dermatology practice. His ability to diagnose, monitor, and manage various skin conditions equips him with firsthand clinical insights essential for relevant and impactful research. Although specific laboratory or advanced research techniques are not detailed in his profile, his clinical experience supports potential development in clinical research methodologies, case study analysis, and patient-centered research. His ongoing academic training is expected to enhance his research capabilities further, enabling him to contribute to clinical trials and evidence-based dermatology studies.

Award and Honors

At this stage of his career, Dr. Takahashi has not yet received formal awards or honors in the field of dermatology or medical research. His professional achievements thus far reflect his dedication to clinical practice and academic growth. As he continues to develop his research portfolio and engage in scholarly activities, there is significant potential for him to earn recognition in the future. Participation in conferences, collaborative research, and contributions to peer-reviewed publications will likely pave the way for future awards and academic honors that acknowledge his efforts in advancing dermatological science.

Conclusion

In conclusion, Dr. Nobuhiro Takahashi is an emerging clinical dermatologist with a promising future in research. His solid educational background, hands-on clinical experience, and keen interest in inflammatory skin diseases demonstrate his dedication to the field. Although he currently has limited research output and formal recognitions, his trajectory indicates potential for future contributions to dermatological science. With continued clinical engagement, research involvement, and academic participation, Dr. Takahashi can develop into a respected researcher who significantly impacts both patient care and dermatological research. His career is well-positioned for continued growth and achievement.

Publication Top Note

  1. Title: A Case of Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma
  • Journal: JEADV Clinical Practice
  • Year: 2025

 

Susumu Eguchi | Medicine and Dentistry | Best Researcher Award

Published on by Shen Awards

Prof. Susumu Eguchi | Medicine and Dentistry | Best Researcher Award

Professor and Chairman from Nagasaki University Graduate School of Biomedical Sciences, Japan

Dr. Susumu Eguchi, M.D., Ph.D., F.A.C.S., F.E.B.S., is a globally recognized expert in the field of liver transplantation, hepatobiliary (HPB) surgery, and regenerative medicine. As a Professor and Chairman at the Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Dr. Eguchi has demonstrated outstanding leadership in both clinical and academic arenas. His medical journey is marked by international exposure, significant research contributions, and a wide array of prestigious editorial appointments. He has actively shaped the advancement of liver surgery, particularly focusing on liver regeneration and hepatocyte-based therapies. Dr. Eguchi’s dedication extends beyond national boundaries, with ongoing collaborations as a visiting professor in China and Kazakhstan, strengthening cross-cultural medical education and research. His active participation in hospital management, international medical center leadership, and nuclear disaster preparedness showcases his multifaceted expertise. Additionally, his editorial influence in several leading surgical and transplantation journals underlines his authority and commitment to knowledge dissemination. Throughout his distinguished career, Dr. Eguchi has significantly contributed to the global medical community and is highly regarded for his ability to combine innovative research with practical surgical excellence. His holistic approach and deep impact in the field make him a prominent figure deserving international recognition.

Professional Profile

Education

Dr. Susumu Eguchi’s educational journey is marked by rigorous academic training and international exposure that shaped his expertise in surgery and transplantation. He graduated from the Nagasaki University School of Medicine in 1992, where he developed a solid foundation in medical sciences. His dedication to deepening his knowledge led him to pursue a Ph.D. at the Nagasaki University Graduate School of Biomedical Sciences, Department of Surgery, from April 1994 to March 1998. This doctoral program was pivotal in advancing his surgical and research competencies, particularly in the hepatobiliary and liver transplantation domains. His international perspective was further broadened during his time at Cedars-Sinai Medical Center in the United States from 1994 to 1997, where he gained valuable experience in surgical research. Dr. Eguchi’s education provided him with a comprehensive blend of clinical, academic, and research-based learning that later translated into his significant contributions to the surgical field. The integration of both Japanese and Western medical training environments equipped him with a unique ability to lead innovative research and clinical practices. His academic progression reflects a consistent pursuit of excellence and positioned him to become an influential leader in liver transplantation and regenerative medicine.

Professional Experience

Dr. Susumu Eguchi has an extensive and distinguished professional career spanning over three decades, characterized by leadership roles in clinical practice, international collaborations, and academic governance. His journey began as a surgical trainee at Nagasaki University Hospital, and he further honed his skills at Cedars-Sinai Medical Center, focusing on surgical research. He has served in key positions such as Chief of Surgery at various hospitals, including National Tsushima Hospital and Nakatsushima Hospital. His international clinical fellowship at Groningen University Hospital in the Netherlands specialized in liver transplantation and hepatobiliary surgery, deepening his expertise in these fields. Since 2012, he has been a Professor at Nagasaki University Graduate School of Biomedical Sciences, where he also took on administrative roles, including Deputy Hospital Director and Director of the International Medical Center and Transplant Center. His global influence is evident through his visiting professorship at Guangzhou First Municipal People’s Hospital and Professor Emeritus roles at prestigious institutions in Kazakhstan and China. Dr. Eguchi’s career reflects a perfect balance of surgical excellence, academic leadership, and international outreach. His continuous involvement in both patient care and research highlights his dedication to advancing surgical techniques and improving patient outcomes globally.

Research Interest

Dr. Susumu Eguchi’s research interests are centered around advancing liver transplantation, hepatobiliary surgery, liver regeneration, and regenerative medicine. His work has significantly contributed to the development of liver surgery techniques and the enhancement of liver transplantation outcomes. A major focus of his research involves hepatocyte-based therapy, exploring the potential of regenerative treatments to restore liver function and improve long-term survival rates for patients. Dr. Eguchi is also deeply invested in liver regeneration studies, aiming to unravel cellular and molecular mechanisms that can accelerate or support liver recovery after surgery or damage. His commitment to hepatobiliary and pancreatic (HPB) surgery research integrates both clinical advancements and innovative therapies, addressing complex surgical challenges. Additionally, Dr. Eguchi has shown interest in disaster response and medical preparedness, applying his medical leadership to nuclear disaster situations. His broad research spectrum allows him to contribute to multidisciplinary fields, including surgical innovation, organ preservation, and post-operative recovery strategies. With his global perspective and cross-institutional collaborations, Dr. Eguchi continues to drive progress in improving surgical outcomes and patient care. His pioneering research offers promising solutions in regenerative medicine and solid organ transplantation, pushing the boundaries of modern surgical practices.

Research Skills

Dr. Susumu Eguchi possesses a wide range of research skills that reflect his technical mastery and innovative approach in the field of surgery and transplantation. He is highly skilled in complex liver surgery, hepatobiliary surgical techniques, and organ transplantation procedures. His research capabilities encompass hepatocyte-based therapy development, liver regeneration studies, and regenerative medicine applications. Dr. Eguchi is adept at designing clinical trials, managing multi-institutional research projects, and applying translational research principles to bridge laboratory findings with patient care improvements. His leadership in surgical research has been recognized internationally, contributing to advancements in both surgical methodologies and post-operative patient management. Moreover, Dr. Eguchi demonstrates strong skills in cross-cultural medical collaboration, contributing to the development of global treatment standards. His editorial roles across multiple high-impact journals also indicate his proficiency in critical peer review, scientific writing, and knowledge dissemination. He is experienced in guiding surgical teams, mentoring young researchers, and overseeing international research initiatives. Additionally, his involvement in disaster preparedness reflects his ability to integrate surgical expertise with public health strategies. Dr. Eguchi’s exceptional surgical and research skills collectively position him as a leading figure in the evolution of liver surgery and transplantation.

Awards and Honors

Dr. Susumu Eguchi has received numerous prestigious certifications and honors throughout his distinguished career, which underline his excellence and global recognition in the surgical community. He is a Fellow of the American College of Surgeons (F.A.C.S.), a Fellow of the European Board of Surgery (F.E.B.S.), a Fellow of the International College of Surgeons (F.I.C.S.), and has been recognized as an IASGO Fellow (FASGO) since 2023. His leadership and contributions have earned him honorary titles, such as Professor Emeritus at both Syzganovs’ National Scientific Centre of Surgery in Kazakhstan and The Second Affiliated Hospital to Nanchang University in China. Dr. Eguchi’s exceptional academic contributions are further demonstrated through his numerous editorial appointments in influential journals, including Transplantation, SURGERY, Hepatology Research, Journal of Hepato-Biliary-Pancreatic Science, and Annals of Gastroenterological Surgery. His editorial influence reflects his standing as an expert in the field and his commitment to advancing global surgical knowledge. These accolades not only validate his exceptional skills and research contributions but also emphasize his role as an international leader and innovator in liver transplantation and hepatobiliary surgery.

Conclusion

In conclusion, Dr. Susumu Eguchi is an outstanding and highly accomplished surgeon, educator, and researcher whose contributions to the fields of liver transplantation, hepatobiliary surgery, and regenerative medicine have had a profound impact both in Japan and internationally. His career is marked by an exceptional blend of clinical excellence, academic leadership, and global collaboration. Dr. Eguchi’s extensive research into liver regeneration and hepatocyte-based therapy offers significant advancements in surgical techniques and patient care. His ability to successfully bridge international academic relationships, lead hospital departments, and manage disaster preparedness initiatives highlights his multifaceted expertise. His prestigious fellowships, editorial leadership roles, and international professorships further attest to his global influence and professional recognition. Although future efforts to showcase quantitative research impact, such as citation metrics, could further solidify his academic profile, his achievements to date are exemplary. Dr. Eguchi continues to inspire the next generation of surgeons and researchers through his innovative work, extensive mentorship, and dedication to improving liver surgery outcomes worldwide. Based on his contributions and leadership, he is an exceptional candidate for recognition as a leading researcher and an ideal recipient of the Best Researcher Award.

Publications Top Notes

1. Transplantation of chemically induced liver progenitors in Nagase analbuminemic rats under liver regenerative stimulus

Authors: Masayuki Fukumoto, Akihiko Soyama, Daisuke Miyamoto, Takanobu Hara, Hajime Matsushima, Hajime Imamura, Mampei Yamashita, Tomohiko Adachi, Kengo Kanetaka, Susumu Eguchi
Year: 2025

2. Association Between Distance to the Transplant Center and Survival Following Living Donor Liver Transplantation

Authors: Hajime Matsushima, Akihiko Soyama, Takanobu Hara, Ayaka Kinoshita, Takashi Hamada, Kazushige Migita, Ayaka Satoh, Hajime Imamura, Tomohiko Adachi, Susumu Eguchi
Year: 2025

3. Effect on short‐term outcomes of the COVID‐19 pandemic following laparoscopic distal gastrectomy and low anterior resection for gastric and rectal cancer: A retrospective study using the Japanese National Clinical Database, 2018–2022

Authors: Masafumi Inomata, Hideki Endo, Tomonori Akagi, Hidefumi Shiroshita, Shigeki Yamaguchi, Susumu Eguchi, Norihito Wada, Yukinori Kurokawa, Yosuke Seki, Yoshiharu Sakai, et al.
Year: 2025

4. Limitations of the proposed lymph node classification in intrahepatic cholangiocarcinoma

Author: Susumu Eguchi
Year: 2025

5. Annual report on National Clinical Database 2021 for gastroenterological surgery in Japan

Authors: Sunao Ito, Arata Takahashi, Hideki Ueno, Shuji Takiguchi, Yoshiki Kajiwara, Yoshihiro Kakeji, Susumu Eguchi, Takanori Goi, Akio Saiura, Akira Sasaki, et al.
Year: 2025

6. Histopathological Downgrading of Borderline Phyllodes Tumor in a Young Patient Following Chemotherapy: A Case Report

Authors: Yuki Hara, Rin Yamaguchi, Ryota Otsubo, Ayako Fukushima, Eiko Inamasu, Momoko Akashi, Michi Morita, Sayaka Kuba, Susumu Eguchi, Keitaro Matsumoto
Year: 2024

7. Efficacy of chemically induced human hepatic progenitor cells from diseased liver against nonalcoholic steatohepatitis model

Authors: Daisuke Miyamoto, Kunihito Matsuguma, Kazuhiro Nagai, Takayuki Miyoshi, Takanobu Hara, Hajime Matsushima, Akihiko Soyama, Takahiro Ochiya, Yasushi Miyazaki, Susumu Eguchi
Year: 2024

8. Current status and future perspectives of robotic liver surgery

Authors: Akihiko Soyama, Takashi Hamada, Tomohiko Adachi, Susumu Eguchi
Year: 2024

9. Essential updates 2022/2023: A review of current topics in robotic hepatectomy

Authors: Tomohiko Adachi, Takanobu Hara, Hajime Matsushima, Akihiko Soyama, Susumu Eguchi
Year: 2024

10. Short‐term outcomes after liver resection with vascular reconstruction: Results from a study with the National Clinical Database of Japan

Authors: Akihiko Soyama, Hiroyuki Yamamoto, Susumu Eguchi, Atsushi Nanashima, Yoshihiro Kakeji, Yuko Kitagawa, Masafumi Nakamura, Itaru Endo
Year: 2024

Guoguo Jin | Medicine and Dentistry | Best Researcher Award

Published on by Shen Awards

Assoc. Prof. Dr. Guoguo Jin | Medicine and Dentistry | Best Researcher Award

Deputy Director from Key Laboratory of Chronic Disease Health Management of Henan Province, China

Dr. Guoguo Jin is an accomplished biomedical researcher specializing in the chemical prevention of tumors. With a strong foundation in pathology and bioengineering, she has steadily developed a research career that bridges cancer biology and cardiovascular complications arising from oncological treatments. Her work delves into the molecular mechanisms underlying tumorigenesis, cardiotoxicity from chemotherapeutic agents, and the identification of therapeutic targets for various cancers, particularly esophageal, gastric, and colon carcinomas. Dr. Jin currently serves as the Deputy Director of both the Key Laboratory of Chronic Disease Health Management and the Department of Scientific Research and Discipline Construction at Fuwai Central China Cardiovascular Hospital. She has led several national and provincial-level research projects and has published extensively in top-tier journals. Her research contributions are complemented by multiple patents aimed at mitigating drug-induced cardiotoxicity. Recognized for her leadership and scientific acumen, she has received accolades such as the Young and Middle-aged Academic Leader title from the Health Commission of Henan Province. Overall, Dr. Jin’s work represents a compelling blend of scientific rigor, clinical relevance, and translational potential. Her continued efforts are likely to yield significant advancements in cancer therapy and patient care.

Professional Profile

Education

Dr. Guoguo Jin began her academic journey in bioengineering, earning her Master’s degree from the School of Bioengineering at Zhengzhou University in July 2011. This foundational training equipped her with critical insights into biomedical sciences and experimental techniques. She then pursued her doctoral studies in pathology and pathophysiology at the Basic Medical College of Zhengzhou University, receiving her Ph.D. in July 2017. During her doctoral program, she was selected for an international joint training opportunity and spent two years (2015–2017) at the prestigious Hormel Institute, University of Minnesota. There, she conducted in-depth research into the signal transduction pathways related to tumorigenesis and its prevention. Her time abroad not only enriched her technical competencies but also exposed her to cutting-edge methodologies in cancer biology. This combination of local and international academic training has laid a solid foundation for her ongoing research into tumor mechanisms and therapeutic strategies. Dr. Jin’s educational background reflects a trajectory of consistent academic excellence and scientific curiosity, establishing her as a capable and knowledgeable researcher in the fields of oncology and pathology.

Professional Experience

Dr. Guoguo Jin currently holds dual leadership roles at Fuwai Central China Cardiovascular Hospital, where she serves as Deputy Director of both the Key Laboratory of Chronic Disease Health Management of Henan Province and the Department of Scientific Research and Discipline Construction. Her professional responsibilities primarily involve overseeing tumor-related research and institutional academic development. Earlier in her career, she gained international experience at the Hormel Institute, University of Minnesota, where she focused on cancer signal transduction pathways. This exposure to high-impact research environments significantly influenced her approach to scientific inquiry. Throughout her career, Dr. Jin has successfully led multiple research projects funded at both national and provincial levels. These projects explore the molecular mechanisms of drug-induced cardiotoxicity, tumor progression, and the discovery of small-molecule inhibitors. Her clinical and translational research activities are closely integrated with her hospital’s goals, enhancing the relevance and impact of her findings. With a strong blend of laboratory management, project leadership, and interdepartmental coordination, Dr. Jin’s professional journey reflects her growth from a bench scientist to an influential figure in medical research administration. Her dual roles in scientific research and academic governance enable her to contribute meaningfully to both science and institutional progress.

Research Interest

Dr. Guoguo Jin’s primary research interest lies in the chemical prevention of tumors, with a focus on uncovering the molecular mechanisms that drive carcinogenesis and treatment-related complications. She is particularly interested in the pathways that regulate tumor initiation and progression in gastrointestinal cancers such as esophageal, gastric, and colon cancer. A significant portion of her work also explores the cardiotoxic effects of chemotherapeutic agents like osimertinib and doxorubicin, aiming to develop strategies to mitigate these adverse outcomes. Her recent studies have investigated the roles of signaling molecules such as WNK1, hnRNPU, AHCY-LDHA, and ZIP8 in cancer development and progression. Dr. Jin is also deeply involved in the identification and evaluation of small-molecule inhibitors and natural compounds like α-mangostin and curcumin for their anti-tumor efficacy. Her research bridges basic science and clinical application, positioning her work at the forefront of translational oncology. Through the development of targeted therapies and predictive biomarkers, she aims to improve both treatment outcomes and quality of life for cancer patients. This integrated focus on cancer biology and cardiotoxicity underlines her commitment to advancing personalized medicine in oncology.

Research Skills

Dr. Guoguo Jin possesses a wide array of research skills, especially in molecular and cellular biology techniques relevant to oncology. She is proficient in signal transduction analysis, gene expression profiling, histone modification studies, and functional validation of oncogenes and tumor suppressors. Her expertise extends to the use of in vitro and in vivo cancer models to study the efficacy and mechanisms of chemopreventive agents. She has demonstrated a high level of competence in utilizing molecular techniques such as Western blotting, qRT-PCR, immunohistochemistry, and chromatin immunoprecipitation assays. Her postdoctoral training at the Hormel Institute allowed her to master advanced techniques for dissecting signaling pathways in cancer. In addition to experimental skills, Dr. Jin has a solid foundation in project design, grant writing, and data analysis. She is also skilled in translating laboratory findings into potential therapeutic applications, as demonstrated by her patents. Moreover, her ability to manage multidisciplinary teams and coordinate with clinical departments enhances the practical relevance of her research. These competencies enable her to effectively lead complex biomedical projects from conceptualization to execution and dissemination.

Awards and Honors

Dr. Guoguo Jin has received multiple awards and honors that underscore her impact and promise in the field of medical research. In February 2024, she was selected as a Young and Middle-aged Academic Leader in Health and Wellness by the Health Commission of Henan Province, a recognition of her leadership in translational cancer research. Later that year, she was awarded a position in the National-Level Talent Cultivation Project for First-Class Discipline in Clinical Medicine at Zhengzhou University. Dr. Jin has also secured several competitive research grants, including the National Natural Science Foundation Youth Project, the Science and Technology Tackling Project by the Department of Science and Technology of Henan Province, and the Outstanding Young Talent Training Program for Health and Technology Innovation. Her innovative research on cancer prevention and cardiotoxicity has led to two patents, further highlighting her commitment to developing clinically relevant solutions. These accolades reflect not only her scientific excellence but also her dedication to advancing health outcomes through rigorous and applied research. The consistent support from national and provincial agencies illustrates her status as a leading figure in her domain.

Conclusion

Dr. Guoguo Jin exemplifies the qualities of a leading researcher with her focused expertise in chemical tumor prevention and translational oncology. Her well-rounded background—from robust academic training to leadership in high-impact research—positions her as a valuable contributor to both the scientific community and clinical practice. Her studies on molecular mechanisms of cancer progression and cardiotoxicity have not only expanded academic understanding but have also offered practical pathways for improving patient outcomes. Through national and provincial grants, influential publications, and patented innovations, she continues to push the boundaries of cancer therapy and prevention. While her research is already making a meaningful impact, future expansion into international collaborations and clinical trials could further elevate her contributions. Overall, Dr. Jin’s career is marked by scientific rigor, visionary leadership, and a commitment to translating research into real-world solutions. She is a highly deserving candidate for recognition through honors such as the Best Researcher Award and is likely to make even greater strides in cancer research in the years to come.

Publications Top Notes

  1. Title: STIP1 drives metabolic reprogramming in esophageal squamous cell carcinoma via AHCY-LDHA axis
    Authors: Jin G, Song Y, Yan M, Fang S, Shao Y, Zhao K, Liu M, Guo Q, Jia X, Zhang C, Wang Z, Liu K, Li X, Zhao S, Guo Z, Dong Z
    Year: 2025

  2. Title: hnRNPU-mediated pathogenic alternative splicing drives gastric cancer progression
    Authors: Jin G, Song Y, Fang S, Yan M, Yang Z, Shao Y, Zhao K, Liu M, Wang Z, Guo Z, Dong Z
    Year: 2025

  3. Title: ZIP8 modulates ferroptosis to drive esophageal carcinoma progression
    Authors: Yang Z, Zhao K, Li X, Yanzhang R, Zhang H, Yu Y, Yan M, Fang S, Li T, Li H, Chu X, Han S, Zhang Z, Teng J, Jin G, Guo Z
    Year: 2025

  4. Title: Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer
    Authors: Jin G, Yan M, Liu K, Yao K, Chen H, Zhang C, Yi Y, Reddy K, Gorja DR, Laster KV, Guo Z, Dong Z
    Year: 2020

  5. Title: Ginger extract inhibits c-MET activation and suppresses osteosarcoma in vitro and in vivo
    Authors: Yanzhang R, Yan M, Yang Z, Zhang H, Yu Y, Li X, Shen R, Chu X, Han S, Zhang Z, Teng J, Li H, Li T, Jin G, Guo Z
    Year: 2025

  6. Title: PDK1-mediated phosphorylation of USP5 modulates NF-κB signalling to enhance osteosarcoma growth
    Authors: Yang Z, Yu Z, Teng J, Yanzhang R, Yu Y, Zhang H, Jin G, Wang F
    Year: 2025

  7. Title: Precision therapy for cancer prevention by targeting carcinogenesis
    Authors: Jin G, Liu K, Guo Z, Dong Z*
    Year: 2024

  8. Title: Decrypting the Molecular Mechanistic Pathways Delineating the Chemotherapeutic Potential of Ruthenium-Phloretin Complex in Colon Carcinoma Correlated with the Oxidative Status and Increased Apoptotic Events
    Authors: Jin G, Zhao Z, Chakraborty T, et al.
    Year: 2020

  9. Title: Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma
    Authors: Zhao Z, Jin G, Yao K, Liu K, Liu F, Chen H, Wang K, Gorja DR, Reddy K, Bode A.M., Guo Z, Dong Z
    Year: 2019

  10. Title: Resveratrol suppresses colon cancer growth by targeting the AKT/STAT3 signaling pathway
    Authors: Li D, Wang G, Jin G, Yao K, Zhao Z, Bie L, Guo Y, Li N, Deng W, Chen X, Chen B, Liu Y, Luo S, Guo Z
    Year: 2019